Real-World Experience with Ropeginterferon Alfa-2b

As treatment perspectives in polycythemia vera evolve, care teams are considering when ropeginterferon alfa-2b may be appropriate and what it takes to integrate it successfully into long-term care.

Courtney Horn, PharmD (Maryland Oncology Hematology), will share real-world experience with:

• Clinical and patient factors influencing earlier use of ropeginterferon alfa-2b
• Barriers related to access, workflow, administration, and patient experience
• Multidisciplinary strategies for treatment initiation and monitoring
• Approaches to patient education and long-term management

For additional information or login assistance, reach out to NCODA’s Jonathan Rivera.